Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CureVac ( (CVAC) ) has provided an announcement.
On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive $740 million and royalties on U.S. vaccine sales. Additionally, CureVac will grant a non-exclusive license to BioNTech and Pfizer for mRNA-based products, which will expand globally upon BioNTech’s acquisition of CureVac. This resolution is expected to streamline CureVac’s operations and strengthen its industry position.
The most recent analyst rating on (CVAC) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac demonstrates a strong overall performance led by its solid financial health and attractive valuation. The technical indicators support a bullish outlook, further enhancing the stock’s appeal. While there is room for improvement in revenue growth, the company’s low leverage and efficient cash flow management contribute significantly to its positive score.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac is a pioneering multinational biotech company founded in 2000, specializing in the development of transformative medicines based on messenger RNA (mRNA) technology. The company focuses on advancing mRNA technology for human medicine, including the production of mRNA vaccines against COVID-19, and is exploring new therapeutic areas such as cancer immunotherapy and prophylactic vaccines. CureVac operates in Germany, the Netherlands, Belgium, Switzerland, and the U.S.
Average Trading Volume: 1,250,409
Technical Sentiment Signal: Hold
Current Market Cap: $1.23B
For detailed information about CVAC stock, go to TipRanks’ Stock Analysis page.